EndoQuest Robotics Announces Installation of the First Endoluminal Surgical System to Advance the Clinical and Procedural Development of the ELS System at Brigham and Women’s Hospital in Boston, Massachusetts

ENDOQUEST Robotics today announced that the company’s proprietary Endoluminal Surgical (ELS) System will be installed at Brigham and Women’s Hospital (BWH) in Boston, MA.  The ELS System is the world’s first endoluminal robotic surgical system that makes it possible for therapeutic endoscopists and surgeons to perform scar-free upper and lower gastrointestinal surgery less-invasively through a trans-oral or trans-anal approach.

“Successful endoluminal surgery requires innovation in technology and procedural techniques,” said Christopher C. Thompson, MD, Professor of Medicine and Director of Endoscopy, Brigham and Women’s Hospital.  “The EndoQuest System is the world’s first fully robotic platform specifically designed for gastrointestinal tract surgery and can enable endoscopists to perform many procedures that are very challenging or not possible today.”

EndoQuest’s Endoluminal Surgical System represents an innovative advance in minimally invasive surgery that combines the flexibility of conventional endoscopy with the advantages of traditional surgical techniques to improve control and outcomes.  With this technology, therapeutic endoscopists and surgeons can perform a range of surgeries by accessing target disease sites directly through the body’s existing lumens. The ELS System design features a proprietary endoscope that works as a flexible and steerable overtube supporting the use of two surgical instruments and a videoscope.  The minimally invasive procedures can be performed using only internal incisions that do not result in visible scarring.  The enhanced capabilities of the robotic ELS System bring endoscopists and surgeons new levels of precision and control they need to use surgical techniques that were not previously possible.

“We are very pleased to partner with Brigham and Women’s Hospital, a global leader in innovation in endoluminal surgery, and look forward to working with them to advance the clinical and procedural development of the ELS System,” said Kurt Azarbarzin, Chief Executive Officer of EndoQuest Robotics.  “We also hope to expand this relationship to include BWH as a center for our planned IDE clinical study in late 2023 and as our first Center of Excellence and training facility in the U.S.”

SourceEndoQuest

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.